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Abstract
Angiogenesis is a balanced process controlled by pro- and anti-angiogenic molecules of which the regulation is not fully
understood. Besides classical gene regulation, miRNAs have emerged as post-transcriptional regulators of angiogenesis.
Furthermore, epigenetic changes caused by histone-modifying enzymes were shown to modulate angiogenesis as well.
However, a possible interplay between miRNAs and histone-modulating enzymes during angiogenesis has not been
described. Here we show that VEGF-mediated down-regulation of miR-101 caused pro-angiogenic effects. We found that
the pro-angiogenic effects are partly mediated through reduced repression by miR-101 of the histone-methyltransferase
EZH2, a member of the Polycomb group family, thereby increasing methylation of histone H3 at lysine 27 and transcriptome
alterations. In vitro, the sprouting and migratory properties of primary endothelial cell cultures were reduced by inhibiting
EZH2 through up-regulation of miR-101, siRNA-mediated knockdown of EZH2, or treatment with 3-Deazaneplanocin-A
(DZNep), a small molecule inhibitor of EZH2 methyltransferase activity. In addition, we found that systemic DZNep
administration reduced the number of blood vessels in a subcutaneous glioblastoma mouse model, without showing
adverse toxicities. Altogether, by identifying a pro-angiogenic VEGF/miR-101/EZH2 axis in endothelial cells we provide
evidence for a functional link between growth factor-mediated signaling, post-transcriptional silencing, and histone-
methylation in the angiogenesis process. Inhibition of EZH2 may prove therapeutic in diseases in which aberrant
vascularization plays a role.
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Introduction
Angiogenesis - the formation of new blood vessels - occurs
during tissue growth and development, but also during wound
healing and cancer [1,2]. Angiogenesis is a balanced process
controlled by pro- and anti-angiogenic molecules [3]. VEGF has
been identified as one of the most potent factors involved in
angiogenesis [4–6]. VEGF, produced in large amounts by cancer
cells during tumor growth, interacts with its receptors VEGFR1
and VEGFR2 thereby causing endothelial cell survival, prolifer-
ation, and sprouting [7].
Recently, it was shown that angiogenesis is also controlled by
miRNAs [8,9]. miRNAs comprise a large group of endogenous
non-coding RNAs that can block mRNA translation or negatively
regulate mRNA stability and thereby play a central role in
regulating gene expression [10,11]. We previously showed that
VEGF signaling in primary endothelial cell cultures caused
overexpression of VEGFR2 in a positive feed-forward loop, which
is at least partly regulated by loss of miRNA-mediated control of
VEGF receptor degradation. Moreover, we found that glioblas-
toma cells, notorious for their VEGF production, elicited a similar
response when co-cultured with endothelial cells [11].
Another class of potential regulators of gene expression is the
group of chromatin modulators involved in histone modification,
such as histone deacetylases [12,13] and histone methyltransfer-
ases [14]. Polycomb group proteins (PcG) function as transcrip-
tional repressors that silence specific sets of genes through
chromatin modification [14]. PcG proteins act together in
polycomb repressive complexes (PRC). PRC2 includes enhancer
of zeste 2 (EZH2), suppressor of zeste 12 (SUZ12), and embryonic
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ectoderm development (EED). EZH2 is the catalytically active
component of PRC2 and is capable of trimethylating histone H3
at lysine 27 (H3K27me3) [15–20]. Expression profiling indicated
that EZH2 transcripts are up-regulated in ovarian carcinoma-
associated endothelial cells [21], and modulated EZH2 expression
was described to affect genes associated with endothelial
differentiation [22,23]. It was also described that EZH2 expression
is regulated by miRNAs including miR-26 [24], miR-214 [25],
and miR-101 [24,26–28].
Here we report that EZH2 is up-regulated in angiogenic
endothelial cells and that miR-101 is down-regulated in primary
endothelial cells exposed to VEGF or glioblastoma cells, as well as
in blood vessel endothelial cells that were isolated from
vascularized glioblastomas from patient samples. We confirm that
EZH2 is a direct post-transcriptional target of miR-101 and that
VEGF-mediated down-regulation of miR-101 results in increased
expression of the histone methyltransferase EZH2 in angiogenic
endothelial cells. Finally, we show that inhibition of EZH2 histone
methyltransferase activity inhibits vascularization in glioblastomas
in vivo, suggesting a possible therapeutic potential for EZH2
inhibitors in the many diseases in which aberrant vacularization
plays a role.
Results
miR-101 directly targets EZH2 and is down-regulated in
tumor-associated endothelial cells
We recently showed that various miRNAs are deregulated in
human brain microvascular endothelial cells (HBMVECs) co-
cultured with U87 glioblastoma cells [11]. Here, a ,3-fold down-
regulation of miR-101 was confirmed by qRT-PCR analysis using
miR-186 and GAPDH as normalization controls, both of which were
uniformly expressed in endothelial cells in the presence or absence of
tumor cells (Fig. 1A). In addition, we examined the expression of
miR-101 in angiogenic endothelial cells derived from gliomas
resected from patients. Hereto, endothelial cells were isolated from
blood vessels derived from three glioblastomas and three grade II
gliomas, as well as from non-neoplastic brain [29]. All tumor samples
were highly angiogenic as confirmed by CD31 immunohistochemical
analysis. We observed reduced miR-101 expression levels in glioma
blood vessels as compared to normal brain vessels, as determined by
qRT-PCR analysis (Fig. 1B). We were particularly interested in miR-
101 since this miRNA was recently shown to interact with EZH2 in
different types of cancer [26,27], and predicted to bind the EZH2 39-
UTR at two sites [30]. To confirm that miR-101 regulates the 39-
UTR of EZH2, we transfected a firefly luciferase (Fluc) reporter
vector encoding the wild type 39-UTR of EZH2 or lacking the EZH2
39-UTR (control) into 293T cells. Overexpression of miR-101 by pre-
miR-101, but not by pre-miR-control, resulted in a decrease in Fluc
expression in the cells expressing the reporter with the 39-UTR of
EZH2. No effects were observed using the control vectors lacking the
EZH2 39-UTR (Fig. 1C).
EZH2 is up-regulated in tumor-associated endothelial
cells
To determine whether EZH2 is overexpressed in angiogenic
endothelial cells we analyzed EZH2 mRNA and protein
expression. We found the expression of EZH2 mRNA to be
increased in HBMVECs after co-culture with human U87
glioblastoma cells (Fig. 2A). In addition, we analyzed EZH2
mRNA expression in glioblastoma blood vessel endothelial cells
resected from patient samples as described above. qRT-PCR
revealed that EZH2 expression levels were up-regulated in
glioblastoma blood vessels as compared to normal brain vessels
(Fig. 2B). The overexpression of EZH2 mRNA in the glioma-
associated endothelial cells was in line with previously described
mRNA expression data of ovarian carcinoma-associated endothe-
lial cells [21]. Upon examination of the EZH2 immunohisto-
chemistry of vascularized glioblastoma and non-neoplastic brain
tissue slices, we noticed positive nuclear staining for EZH2 in the
endothelial cells of newly formed blood vessels in the glioblastoma
samples, but not in the non-neoplastic brain tissues (Fig. 2C).
These results indicate an inverse correlation of miR-101 and
EZH2 expression levels in angiogenic endothelial cells and led us
to further investigate the role of deregulated EZH2 expression
during angiogenesis.
VEGF down-regulates miR-101 expression in endothelial
cells resulting in EZH2 up-regulation
To determine whether EZH2 expression in HBMVECs could
be suppressed by up-regulation of miR-101 we performed Western
blot analysis for EZH2 after transfection of cells with pre-miR-101,
siRNA directed against EZH2, or non-related control oligonucle-
otides. We also included lysates from cells treated with the S-
adenosylhomocysteine hydrolase inhibitor DZNep, a potent
inhibitor of EZH2 histone methyltransferase activity [31,32].
Treatment of the endothelial cells with DZNep, EZH2 siRNA, or
pre-miR-101, all markedly reduced EZH2 protein levels. EZH2
gene silencing also decreased histone 3 methylation at lysine 27, as
determined by Western blot (Fig. 3A). To establish whether tumor-
derived soluble factors are sufficient to induce differential
expression of miR-101 and EZH2, HBMVEC cells were cultured
in endothelial basal medium (EBM), EBM supplemented with an
angiogenic cocktail (EGM), or EBM conditioned culture medium
derived from U87 glioblastoma cells (U87cm). We used qRT-PCR
to show down-regulation of miR-101 levels in HBMVECs
cultured in U87cm or EGM (Fig. 3B). Interestingly, we were not
able to measure significant and reproducible miR-101 down-
regulation in HUVECs upon exposure to U87 conditioned
medium, in contrast to HBMVECs (Fig. S1A). In parallel to the
miR-101 down-regulation, EZH2 protein levels were up-regulated
in HBMVECs grown in either U87cm or EGM (Fig. 3C) as well as
in HUVECs grown in EGM but not reproducibly in HUVECs
grown in U87cm (Fig. S1B). EGM and U87cm both contain many
growth factors. VEGF in particular, appears to play a major role
in angiogenesis [11,33]. To address the role of VEGF in regulating
miR-101 and EZH2 expression, HBMVECs were cultured for
24 h in EBM supplemented with different amounts of VEGF, or in
EGM, after which total RNA was isolated and miR-101 and
EZH2 expression levels were determined by qRT-PCR (Fig. 3D).
An amount of 1 ng/ml of VEGF was sufficient to significantly
down-regulate miR-101 levels in HBMVECs and at higher doses
its inhibitory effect almost equalled that of the angiogenic cocktail
used in EGM medium, indicating that VEGF plays an important
role in miR-101 regulation in endothelial cells. In parallel to miR-
101 down regulation, EZH2 levels were significantly increased
after VEGF stimulation of HBMVECs.
mRNA profiling of VEGF and EZH2 modulated
endothelial cells
To gain insights into target genes affected by EZH2 mediated
gene silencing in the presence of VEGF stimulation, we suppressed
EZH2 in HBMVECs cultured in the presence of VEGF and
subsequently isolated the RNA. We then used Agilent 44K gene
expression arrays to determine mRNA profiles and identify genes
whose expression levels were changed by EZH2 silencing in the
presence of VEGF. Simultaneously, we used expression arrays to
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identify a pro-angiogenic gene profile in HBMVECs stimulated by
VEGF. VEGF stimulation significantly induced elongation of the
endothelial cells (Fig. 4A) indicating angiogenic activation [34].
EZH2 knockdown efficiency and H3K27me3 reduction in the array
samples were confirmed by Western blot analysis (Fig. 4B). To
identify which VEGF target genes are potentially depending on
EZH2 regulation a comparison was made between the top 5
percentile genes whose expression was increased after EZH2
silencing (n=1865) and the top 5 percentile genes down-regulated
by VEGF stimulation (n=1853) (Fig. 4C, D). We identified a
significant overlap of 138 genes (Fig. 4E) in both sets (p,10-9). Of
note, the recently reported EZH2 target gene VASH1 [35] was also
identified in the set of genes both regulated by VEGF and EZH2.
Inhibition of EZH2 reduces endothelial tubule formation
in vitro
To further assess the function of EZH2 up-regulation in
angiogenesis, we examined EZH2 inhibition in angiogenic
HBMVECs in culture. HBMVECs were cultured in EBM,
EGM, or were co-cultured with U87 glioblastoma cells expressing
GFP (U87-GFP) in EBM, all on a Matrigel substratum to promote
tubule formation. After treatment of HBMVECs with DZNep, or
transfection with pre-miR-101, EZH2 siRNA, or controls, and
subsequent culturing on Matrigel, we analyzed endothelial tubule
length and tubule branching. Tubules were visualized by a
combination of light and fluorescence microscopy, to visualize the
endothelial cells and U87-GFP cells, respectively (Fig. 5A). Up-
regulation of miR-101 resulted in a significant decrease in total
tubule length and tubule branching (Fig. 5A and B). In addition,
treatment with EZH2 siRNA and DZNep also inhibited growth
factor- or glioblastoma-induced HBMVEC tubule network
formation (Fig. 5A and B). In HUVECs treatment with EZH2
siRNA and pre-miR-101 also led to a significant decrease in tubule
length. DZNep treatment did not significantly reduce tubule
length in HUVECs, although the quality of the resulting networks
seemed less than in the control condition (Fig. S1C and D). These
Figure 1. miR-101 is down-regulated in angiogenic endothelial cells and directly targets EZH2. (A) Down-regulation of miR-101 in
HBMVECs exposed to U87-GFP glioblastoma cells confirmed by qRT-PCR analysis. RNA extracted from CD31+ HBMVECs cultured in the presence or
absence of U87 glioblastoma cells was analysed by qRT-PCR with primers/probes specific for miR-101 and miR-186. The data were normalized to the
levels of GAPDH mRNA in each sample. (B) RNA extracted from individual glioma endothelial samples was analyzed by qRT-PCR for expression levels
of miR-101 and miR-186. All values were normalized to GAPDH mRNA levels in the same samples. (C) Relative expression of firefly luciferase activity as
determined by reporter assay in 293T cells. Luciferase expression was determined 24 h after co-transfection of miR-101 precursor or control miRNA.
Luciferase activity of the EZH2 39UTR reporter vector in the miR-101 transfected cells was significantly reduced as compared to the controls. (n = 3)
Error bars indicate s.d. *p,0.05, ***p,0.001 by t test.
doi:10.1371/journal.pone.0016282.g001
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results indicate that EZH2 is involved in endothelial tubule
formation.
Inhibition of EZH2 reduces endothelial migration and
invasion in vitro
Endothelial migration and invasion are two other essential steps
in the tumor vascularization process. In order to determine the
effect of EZH2 inhibition on growth factor-induced endothelial
cell migration, scratch assays were performed. HBMVEC cells
were treated with either pre-miR-101, EZH2 siRNA, or DZNep,
and cultured in EGM. To promote migration a scratch was made
in the confluent HBMVEC monolayer and the migration distance
of the HBMVECs into the scratched area was measured and
quantitated 24 h later (Fig. 6A and B). Inhibition of EZH2 by pre-
miR-101, EZH2 siRNA, or DZNep, resulted in a significant
decrease in HBMVEC migration (Fig. 6A and B). We did not
detect significant differences in HBMVEC proliferation over the
same period, only after a 72 h period HBMVECs proliferation
was negatively affected (Fig S2A and B). To further evaluate the
effects of miR-101/EZH2 modulation on endothelial invasion, a
Boyden chamber Transwell assay was used. HBMVECs trans-
fected with pre-miR-101 were seeded on the porous membrane of
the Transwell insert and the ability of these cells to invade into the
lower compartment was measured after 24 h. HBMVECs
transfected with pre-miR-101 showed a 60% decrease in their
ability to invade compared to control transfected cells, as
visualized by Hoechst staining and quantification of the number
of invaded cells (Fig. 6C and D). Similar results were observed
after treatment with the EZH2 inhibitor DZNep or EZH2 knock
down by siRNA (Fig. 6C and D). These results support a
functional role for the miR-101/EZH2-axis in the angiogenesis
process, where deregulation of EZH2, through EZH2 knockdown
or by using the EZH2 small molecule inhibitor DZNep, mimics
the anti-angiogenic effects observed after up-regulating miR-101
levels.
EZH2 inhibitor DZNep reduces glioblastoma-induced
angiogenesis in vivo
To study the anti-angiogenic effect elicited by EZH2 inhibition
in vivo, we used a subcutaneous glioblastoma mouse model and the
EZH2 inhibitor DZNep. U87 glioblastoma cells, stably expressing
the bioluminescence reporter Fluc and the fluorescence reporter
mCherry, were implanted in the flank of nude mice (N= 10).
Intravenous (i.v.) injections of the EZH2 histone methyltransferase
inhibitor DZNep (0.07 mg/kg) were performed on day 3, 5 and 7
after implantation of the cells followed by weekly injection. Tumor
growth was monitored using in vivo Fluc bioluminescence imaging
after injection of its substrate D-Luciferin and acquiring photon
counts using a CCD camera. Tumor volume in control mice
increased exponentially over time, while tumors in mice treated
with DZNep showed reduced growth (Fig. 7A). Ki67 staining of
tumor sections revealed areas with proliferating cells in both
DZNep treated and control mice (Fig. S3A). Prior to sacrifice, the
mice were injected with Lectin-FITC to mark blood vessels. Upon
immunofluorescence analysis of tumor tissue slices we noticed that
DZNep treatment significantly reduced both the number and the
size of the tumor blood vessels, as illustrated by Lectin-FITC blood
vessels of mCherry-expressing glioblastoma sections (Fig. 7B and
Fig. 7C). This indicates that the EZH2 inhibitor DZNep can
inhibit angiogenesis in vivo, and suggests a possible therapeutic
potential for EZH2 inhibitors in the many diseases in which
aberrant angiogenesis plays a critical role.
Discussion
We have analyzed miR-101 expression in primary HBMVECs.
We showed that VEGF down-regulates the expression of miR-101
resulting in increased EZH2 protein expression and causing a pro-
angiogenic response in the endothelial cells. Further, we show that
this response can be overcome by pharmacological targeting of
EZH2 in vitro and in vivo using the histone methyltransferase
inhibitor DZNep. Altogether these results support a role for
diminished miR-101-mediated suppression of EZH2 in promoting
neovascularization.
Formation of new blood vessels requires endothelial cells to
undergo a balanced angiogenic switch. This involves increased
expression and secretion of growth factors like VEGF. VEGF
modulates destabilization, proliferation, invasion, and sprouting of
Figure 2. EZH2 is up-regulated in angiogenic endothelial cells
and is controlled by miR-101. (A) Overexpression of EZH2 in
HBMVECs exposed to U87-GFP glioblastoma cells confirmed by qRT-
PCR analysis. RNA extracted from CD31+ HBMVECs cultured in the
presence or absence of U87 glioblastoma cells was analysed by qRT-
PCR with primers specific for EZH2. The data were normalized to the
levels of GAPDH mRNA in each sample. (B) RNA extracted from
individual glioma endothelial samples was analyzed by qRT-PCR for
expression levels of EZH2. All values were normalized to GAPDH mRNA
levels in the same samples. (n = 3) Error bars indicate s.d. *p,0.05,
***p,0.001 by t test. (C) Immunohistochemical staining for EZH2, or
EZH2 and CD31, in glioblastoma blood vessels. While glioblastoma
sections show positive nuclear staining for EZH2 in tumor blood vessels,
staining is absent in NNB. In the top panels EZH2 stains brown and
arrows indicate blood vessels. In the bottom panels EZH2 stains purple
and CD31 stain brown. Scale bar = 50 mm (top panels) or 15 mm
(bottom panels).
doi:10.1371/journal.pone.0016282.g002
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vessels, thereby orchestrating the formation of neovasculature via
signaling through its receptors VEGFR1 and VEGFR2. The
proper execution of these processes relies on a concerted action of
multiple proteins. It is now clear that miRNAs can orchestrate
specific biological processes through post-transcriptional regula-
tion of gene expression. It has also been shown that specific
miRNAs are responsible for regulation of endothelial gene
expression during angiogenesis [36–38]. To determine the miRNA
signature of endothelial cells, Poliseno and colleagues generated
miRNA expression profiles of HUVECs. They identified 27 highly
expressed miRNAs, 15 of which were predicted to regulate the
expression of receptors for angiogenic factors [8]. We recently
showed that the miRNA expression profile of HBMVECs was
modulated upon exposure of these brain endothelial cells to
glioblastoma cells [11]. Further, it was shown that endothelial
miRNAs can be deregulated by exposure to VEGF [11,38,39].
Here we show that U87 conditioned medium and VEGF cause
down-regulation of miR-101 in HBMVECs, subsequently result-
ing in up-regulation of the PcG protein EZH2. Interestingly, we
were not able to measure significant and reproducible miR-101
down-regulation in HUVECs upon exposure to U87 conditioned
medium, in contrast to HBMVECs. These results indicate a
discrepancy between miR-101 regulation in HUVECs and
HBMVECs in the context of glioma. However, also in HUVECs
EZH2 protein levels could be modulated by EZH2 siRNA, pre-
miR-101 or DZNep, and this affected tubule formation. In
addition to the mechanism of U87cm and VEGF-suppressed miR-
101-mediated translational repression of EZH2 that we describe,
Lu et al. have recently shown that VEGF can also increase EZH2
promoter activity [35]. Further research is warranted in order to
investigate the different modes of EZH2 regulation in different
types of endothelial cells and whether these mechanisms are
mutual exclusive.
We confirmed that EZH2 translation is suppressed by miR-101.
It was recently shown that miR-101 can regulate EZH2 expression
in cancer cells and affects cancer cell migration and invasion
[26,28]. Moreover, it was described that EZH2 can be regulated
by miR-26 [24] and miR-214 [25]. Of note, we found both miR-
26 and miR-214 to be expressed in HBMVECs (data not shown).
However, in primary HBMVECs exposed to glioblastoma cells we
found miR-26 and miR-214 not to be deregulated [11]. Here, we
show that EZH2 up-regulation in angiogenic brain endothelial
cells can be caused by reduced suppression by miR-101, although
at this point we cannot exclude that miR-26, miR-214, or other
miRNAs, also affect translation of EZH2 in angiogenic endothelial
cells.
EZH2 promotes cancer cell proliferation in vitro and in vivo [40–
43]. This indicates a potential dual role for EZH2 in endothelial
cells and in glioma cells. Regarding the effects of EZH2 inhibition
in vivo, we performed Ki67 staining on tumor slices of mice treated
Figure 3. VEGF down-regulates miR-101 expression in endothelial cells resulting in EZH2 up-regulation. (A) HBMVECs protein
expression analysis of EZH2 and H3K27me3 following transfection of HBMVECs with pre-miR-101, EZH2 siRNA, non-related control molecules or
treatment with DZNep. Numbers indicate relative EZH2 protein expression normalized against b-Actin expression. (B) Inhibition of miR-101 in
HBMVECs exposed to U87 secreted factors was confirmed by qRT-PCR analysis. RNA extracted from HBMVECs cultured in EBM, EGM or EBM derived
from U87 glioblastoma cells was analyzed by qRT-PCR with primers specific for miR-101. The data were normalized to the levels of GAPDH mRNA in
each sample. (C) HBMVECs protein expression analysis of EZH2 following culturing in either EBM, EGM or EBM derived from U87 glioblastoma cells.
Numbers indicate the relative expression of EZH2 compared to cells cultured in EBM. (D) HBMVECs were grown in EBM supplemented with different
amounts of VEGF for 24 h, after which RNA was isolated to determine the expression levels of miR-101and EZH2 by qRT-PCR. The data were
normalized to the level of GAPDH mRNA in each sample. (n = 3) Error bars indicate s.d. *p,0.05, ***p,0.001, t test.
doi:10.1371/journal.pone.0016282.g003
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Figure 4. mRNA profiling of VEGF and EZH2 modulated endothelial cells. (A) Primary human brain microvascular endothelial cells
(HBMVECs) were cultured in the absence (top) or presence (bottom) of VEGF. (B) Western blot analysis of EZH2 and H3K27me3 expression in
HBMVECs upon silencing of EZH2 by EZH2 siRNA. (C) Heatmap representation of top 5% percentile genes up-regulated by EZH2 knock down or
down-regulated by VEGF stimulus, the overlapping section of genes regulated by both EZH2 knock down and VEGF stimulus is shown on the left. The
top bar represents Log2 fold change ratios of EZH2kd (all .0), the bottom bar represents Log2 fold change ratios of VEGF stimulus (all,0). (D) Venn
diagram showing a significant overlap of EZH2 regulated and VEGF regulated genes. Top 5% percentile genes up-regulated by EZH2 knock down or
top 5% percentile genes down-regulated by VEGF stimulus were considered potential targets. (E) Detail of heatmap, showing the cluster of genes
that are regulated by both EZH2 knock down and VEGF stimulus.
doi:10.1371/journal.pone.0016282.g004
Figure 5. Inhibition of EZH2 reduces endothelial tubule formation in vitro. (A) HBMVECs were cultured on Matrigel coated plates in EBM,
EGM, or EBM supplemented with U87-GFP cells. Scale bar = 450 mm. Inhibition of EZH2 in HBMVECs, either by transfection with pre-miR-101, EZH2
siRNA, or treatment with DZNep significantly reduced tubule formation as compared to control cells. Tubule formation was assessed as tubule length
and branching. (B) Quantitation of tubule length and branching using ImageJ software. (n = 3) Error bars indicate s.d. *p,0.05, ***p,0.001, t test.
doi:10.1371/journal.pone.0016282.g005
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with or without the EZH2 inhibitor DZNep. Although we found a
significant reduction in the number of blood vessels in the DZNep
treated tumors we also noticed that proliferation of the glioma cells
was still evident (Fig. S3), suggesting that the observed reduction in
blood vessels under these conditions was - at least partly - caused
by the inhibitory effect of DZNep on the blood vessel endothelial
cells, paralleling the results of our in vitro angiogenesis assays.
However, we do not exclude possible partial effects of DZNep on
glioma cell proliferation in vivo and a consequent reduction in
blood vessel number. It should be noted that our in vivo results were
obtained in an immune-compromised setting, it would be also of
interest to study the effects of EZH2 inhibition in a syngeneic
immune-competent model.
Inhibition of up-regulated EZH2 in angiogenic endothelial cells
caused reduced migration, invasion, and tubule formation in vitro
and diminished blood vessel formation in glioblastoma tumors in
vivo. Here, we describe a new role for the histone methyltransferase
EZH2 to stimulate a pro-angiogenic phenotype of endothelial
Figure 6. Inhibition of EZH2 reduces endothelial migration and invasion in vitro. (A) HBMVEC monolayer cultures were scratched. Images
were acquired directly after scratching (t = 0) and 24 h later (t = 24). The migration front is indicated by the dashed lines. Scale bar = 450 mm.
Inhibition of EZH2 in HBMVECs, either by transfection with pre-miR-101, EZH2 siRNA or treatment with DZNep significantly reduced migration as
compared to control. (B) Quantitation of endothelial cell migration into the scratched area using ImageJ software. (C and D) HBMVECs were
transfected with pre-miR-101, EZH2 siRNA, non-related control molecules, or treated with DZNep, incubated on a Transwell system and subsequently
analyzed for invasion capability. EZH2 inhibition, either through pre-miR-101, EZH2 siRNA or DZNep, significantly decreased invasion as shown by
Hoechst staining. Scale bar = 225 mm. (n = 3) Error bars indicate s.d. *p,0.05, ***p,0.001, t test.
doi:10.1371/journal.pone.0016282.g006
Figure 7. EZH2 inhibitor DZNep reduced glioblastoma-induced angiogenesis in vivo. (A) A total of 16106 U87-Fluc-mCherry cells were
implanted s.c. and imaged with a CCD camera 3 days later. At days 3, 5 and 7 after implantation followed by weekly injection, one set of mice was
injected i.v. with DZNep and another set with PBS. Tumor growth was monitored by in vivo bioluminescence imaging. (B) Lectin-FITC was injected i.v.
prior to sacrificing the mice and was used to determine the tumor blood vessels. (C) Quantification of (B). (n = 5) Error bars indicate s.d. *p,0.05,
***p,0.001, t test.
doi:10.1371/journal.pone.0016282.g007
miR-101 Regulates Angiogenesis
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cells. Inhibition of EZH2 by pre-miR-101, EZH2 siRNA, or the
small molecule inhibitor DZNep shifted the pro-angiogenic status
to a more stationary phenotype. Previously, expression profiling of
EZH2-regulated genes indicated that EZH2 can act as a bona fide
oncogene that stimulates an ‘active’ cell status by trimethylating
lysine 27 of histone H3 [26,40–46]. In addition, it was described
that EZH2 suppression, besides loss of H3K27me3, resulted in
increased H3 acetylation, and that EZH2 modulation can affect
the regulation of genes involved in endothelial differentiation
[22,23]. Histone deacetylase proteins were also described to affect
angiogenesis [12,13] and to revert EZH2-mediated gene silencing
[40,47]. In endothelial cells it remains to be investigated how
histone modifications can affect the balance towards a more pro-
angiogenic cellular state. Here we provide evidence of a functional
link between growth factors, miRNAs, and the histone methyl-
transferase EZH2 in the angiogenesis process.
Materials and Methods
Cells
Human brain microvascular endothelial cells (HBMVECs; Cell
Systems ACBRI-376) were cultured in EGM medium (Lonza).
293T cells and U87 cells (U-87 MG; ATCC) were cultured in
DMEM containing 10% FBS and antibiotics. U87-Fluc-mCherry
and U87-GFP cells were produced by stably transducing U87 cells
with CMV-controlled expression cassettes using lentiviral vectors.
RNA isolation
Total RNA was isolated from HBMVECs, primary endothelial
cells isolated from normal brain and gliomas. RNA isolation was
carried out by adding 600 ml lysis buffer from the miRVANA
miRNA isolation kit (Ambion) to the cell pellets. The isolation of
endothelial cells from normal human brain and human gliomas is
described elsewhere [48].
miRNA modulation
50 nM of pre-miR-101 (Ambion) or pre-miR-control (Ambion)
oligonucleotides were transfected into HBMVECs using Lipofec-
tamin2000 (Invitrogen), according the manufacturer’s protocol.
For the inhibition of EZH2, 50 nM of EZH2 siRNA (Qiagen) was
transfected into HBMVECs, siRNA-AF or non-targeting oligonu-
cleotides (Qiagen) were used as controls. After 5 h the transfection
medium was replaced by EGM until further analysis.
Quantitive RT-PCR
Quantitive RT-PCR (qRT-PCR) analysis was used to deter-
mine the relative expression levels of miR-101, miR-186, EZH2,
and GAPDH mRNA in HBMVECs. Total RNA was isolated
using the miRVANA miRNA isolation kit. Equal amounts of RNA
were converted into cDNA using miR-101, miR-186, EZH2, and
GAPDH RT primers (Applied Biosystems and Qiagen, according
to the manufacturer’s protocol). Subsequently, quantitive PCR
was performed using primers and materials from Applied
Biosystems. The Ct values were used to calculate the relative fold
difference in miRNA or mRNA levels. All experiments were
performed using biological triplicates and experimental duplicates.
The data were normalized to miR-186 and/or GAPDH
expression levels. Primers used were:
human EZH2 59-CCTGAAGTATGTCGGCATCGAAA-
GAG-39 (forward)
59-TGCAAAAATTCACTGGTACAAAACACT-39 (reverse)
human GAPDH 59-GTCGGAGTCAACGGATT-39 (forward)
59-AAGCTTCCCGTTCTCAG-39 (reverse)
Luciferase miRNA reporter assay
293T cells were transfected with firefly luciferase reporter
vectors containing EZH2 wt or control 39-UTR [24]. At 4 h after
transfection, the cells were transfected again with 50 nM miR-101
precursor (Ambion) or controls (Ambion). The cells were lysed
after 24 h, and luciferase activity was measured using a
luminometer. A total of 100 ng of pCSCW-Gluc [49] was co-
transfected and used to normalize the firefly luciferase values
expressed from the EZH2 39UTR report constructs.
Western blot analysis
72 h after transfection with 50 nM of oligonucleotides or
treatment with 5 mM DZNep, or after 24 h of culturing in either
EBM, EGM or EBM conditioned culture medium derived from
U87 glioblastoma cells, HBMVECs were washed, trypsin treated
and harvested, centrifuged (4 min at 1200 rpm) and washed with
ice-cold PBS for two times and subsequently resuspended in RIPA
buffer including protease inhibitor. After 1 h cells were centrifuged
for 10 min at 10,000 rpm and 4uC. Supernatant was mixed with
Laemmli buffer (Bio-RAD) including b-mercaptoethanol and
heated at 97uC. 30 mg of protein was loaded on a 10% SDS-
polyacrylamide gel and separated for 1 h at 100 V on an
electrophoresis system (Bio-Rad). Next, proteins were transferred
to PVDF membranes overnight at 30 V and 4uC by means of blot
buffer (TRIS/glycine/methanol). After incubating the PVDF
membranes with PBS for 15 min they were blocked with 5%
milk in PBS-T for 1 h. Membranes were incubated for 1 h with
purified mouse anti-EZH2 mAb (BD biosciences) at 1:1,000
dilution in blocking solution (1% milk in PBS-T) and mouse anti-
Actin (Millipore, MAB1501R) at 1:50,000 dilution or for 24 h with
rabbit anti-H3K27Me3 (1:1,000; Upstate Biotechnology). Mem-
branes were washed with PBS-T four times for 15 min.
Subsequently, membranes were incubated for 1 h with horserad-
ish peroxidise (HRP) anti-mouse IgG (DAKO) at 1:3,000 dilution
in 1% block buffer to detect primary anti-EZH2 antibody and
anti-Actin antibody or HRP anti-rabbit IgG (DAKO) at 1:3,000
dilution to detect anti-H3K27Me3 antibody. Membranes were
washed again with PBS-T four times for 15 min. ECL detection
solution (GE healthcare) was used to detect protein levels. Levels
were visualized on X-ray film (GE healthcare) and quantified using
ImageJ software (NIH Image). Actin intensities were used to
normalise EZH2 levels. Normalised EZH2 intensities were used to
calculate the relative expression level of EZH2.
Immunohistochemical staining
Paraffin sections of human glioblastoma tissue and neocortex
were stained with monoclonal mouse anti-EZH2 (BD biosciences)
at 1:300 diluted in antibody solution (Immunologic) for 1 h at
room temperature. Sections were washed in PBS three times and
incubated with secondary antibody (EnvisionHRP) for 30 min at
room temperature. After washing in PBS for three times, positive
reactions were visualized by incubating the sections with stable
3,3-diaminobenzidine for 10 min. In case of double staining, the
sections were subsequently incubated with anti-CD31 (DAKO) at
1:50 diluted in antibody diluent for 1 h at room temperature,
washed three times in PBS, incubated with a biotinylated rabbit
anti-mouse secondary antibody (DAKO) at 1:100 diluted in
antibody diluent for 30 min at room temperature, washed in PBS
three times and finally incubated with a streptavidin alcalic
phosphatase complex (Roche) at 1:100 diluted in antibody diluent
for 1 h at room temperature. Liquid Permanent Red chromogen
was used to visualize positive reactions. After washing in distilled
water, the sections were counterstained with hematoxylin for
1 min and analyzed using microscopy.
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Microarray expression analysis
mRNA expression arrays were performed at the VUMC array
core facility. HBMVECs cultured in EBM + VEGF (10 ng/ml)
were compared to HBMVECs cultured in EBM only and
HBMVECs transfected with EZH2 siRNA and cultured in EBM
+VEGF (10 ng/ml) were compared to HBMVECs transfected with
control siRNA and cultured in EBM + VEGF (10 ng/ml). Total
RNA was isolated after 24 h of culturing using TRIzol reagent
(Invitrogen) according to the manufacturer’s protocol. RNA was
quantified using a Nanodrop ND 1000 spectrophotometer
(Nanodrop Technologies). RNA integrity was assessed using the
Agilent 2100 Bioanalyzer (Agilent) and RNA 6000 Nano LabChip
kit (5065–4476). RNA integrity numbers (RIN) of .9.0 were
considered as good quality RNA. RNA samples were labeled using
the Agilent Low RNA Input Linear Amplification Kit Plus (5188–
5340) according to the manufacturer’s protocol. Briefly, 500 ng of
total RNA was amplified and reverse transcribed to cDNA using
T7-polymerase and subsequently labeled with Cy3 or Cy5. Dye
incorporation was measured using a Nanodrop ND-1000 spectro-
photometer. Subsequently, cRNA was hybridized using the Agilent
Gene Expression Hybridization Kit (5188–5242), according to the
manufacturer’s protocol. Briefly, 825 ng of Cy3 labeled cRNA was
mixed with 825 ng of Cy5 labeled cRNA, fragmented for 30 min at
60uC in the dark and hybridized on an Agilent Hybridization
Chamber Gasket Slide (G2534-60011) in a rotation oven at 65uC
for 17 h. Slides scanned using an Agilent Microarray Scanner
(G2565BA). Image analysis was performed using feature extraction
software version 9.5 (Agilent Technologies). The Agilent GE2-
v5_95 protocol was applied using default settings.
Data pre-processing and analysis was performed using the R-
Bioconductor package Limma [50]. A robust Edwards back-
ground correction was applied. Within-array and between-array
normalization was performed using loess and scale standardiza-
tion. For EZH2 siRNA transfected versus control siRNA
transfected cells the highest 5 percentile of differentially expressed
log2 expression ratios [range log2 expression ratio: 0.32–1.76]
were selected as potential target genes for EZH2. For EBM +
VEGF (10 ng/ml) versus EBM cultured cells the lowest 5%
percentile differentially expressed log2 expression ratios [range
log2 expression ratio: 24.20–20.48] were selected as potential
target genes for VEGF induced EZH2 gene silencing. Subse-
quently, an overlap set of genes both induced by EZH2 knock
down and reduced by VEGF was established as a VEGF-induced-
EZH2-target gene set.
In vitro Matrigel assay
A Matrigel (BD biosciences) assay was performed to assess
endothelial tube formation in vitro. 48-well Plates were coated with
75 ml of Matrigel per well and incubated at 37uC for 15 min. 72 h
after transfection with 50 nM of oligonucleotides or treatment
with 5 mM DZNep, HBMVECs were harvested and suspended in
either EBM, EBM supplemented with U87-GFP cells or EGM.
Per well, 60,000 HBMVECs were plated and maintained at 37uC.
At least 3 random pictures were taken per well using a digital
camera system (Leica), 16 h after plating. The images were
analyzed for total tube length and number of branching points
using the software program ImageJ. Experiments were performed
in triplicate, repeated at least once and judged in a double blind
fashion by two observers. Statistical analysis of the results of 3
experiments was performed by Student t-test.
Wound healing assay
HBMVECs were cultured in EGM in 24-wells plates and were
transfected with 50 nM of oligonucleotides or treated with DZNep
(5 mM). At 72 h after transfection an artificial wound was created
using a pipette tip after which the cells were further incubated. To
analyse cell migration into the wound, pictures were taken at 0 h
and 24 h using a digital camera system coupled to a microscope.
ImageJ was used to determine the migration distance (in mm) as
the reduction of the width of the open area. Statistical analysis of
the results of 3 experiments was performed by Student’s t-test.
Cell invasion assay
HBMVEC migratory function was analysed using a Boyden
chamber assay. A 24-well Transwell system (Corning) was used,
with each well containing a permeable Transwell insert containing a
6.5 mm polycarbonate membrane with 8 mm pores. The inserts
were coated with 4x diluted basement membrane extract (Trevigen)
and incubated overnight in 5% CO2 at 37uC. At 72 h after
transfection with 50 nM of oligonucleotides or treatment with 5 mM
DZNep cells were starved for 24 h and harvested in serum free
medium. Per insert 25,000 HBMVECs were subsequently placed
on the membrane. The inserts were immersed in a 24-well plate that
was filled with EGM growth medium culture media. After
incubation for 24 h, the membrane was washed briefly with PBS.
The upper side of the membrane was then wiped gently with a
cotton ball. The membrane was then fixed in 4% formaldehyde and
stained with Hoechst. The magnitude of HBMVEC migration was
evaluated by counting the migrated cells in 3 random high-power
(5x) microscope fields. Statistical analysis of the results of 3
experiments was performed by Student’s t-test.
In vivo glioblastoma angiogenesis model
All animal studies were approved by the Massachusetts General
Hospital Review Board. Protocol approved by the MGH Subcom-
mittee on Research Animal Care (SRAC) - OLAW assurance
number A3596-01. Nude mice were anesthetised with i.p. injection
of xylazine (5 mg/kg) and ketamine (100 mg/kg). 50 ml containing
16106 U87-Fluc-mCherry cells was pre-mixed with an equal
volume of matrigel (BD biosciences) and implanted in the flanks of
nude mice. DZNep was administered intravenously to tumor-
bearing mice at a dose of 0.07 mg/kg diluted in 100 ml PBS at day 3,
5 and 7 after tumor implantation, followed by weekly injection. Mice
were anesthetized as above and Fluc imaging was performed 10 min
after intravenous injection of 150 ml beetle D-luciferin (4 mg/kg
body weight) (Xenogen), and recording photon counts over 5 min
using a cooled CCD camera with no illumination. Dim polychro-
matic illumination was used to take a light image of the animal.
Visualization was performed using CMIR-Image, a program
developed by the Center for Molecular Imaging Research using
image display and analysis suite developed in IDL (Research Systems
Inc., Boulder, CO). An intensity contour procedure to identify
bioluminescence signals with intensities significantly greater than the
background was used to define regions of interest. The mean,
standard deviation and sum of photon counts in these regions were
calculated as a measurement of Fluc activity. Prior to sacrifice the
mice were injected intravenously with 150 ml (1 mg/ml) Lectin-
FITC (Vector Laboratories) to mark the blood vessels. Animals were
sacrificed by transcardial perfusion with 4% paraformaldehyde in
PBS under deep anaesthesia. Tumors were removed, post-fixed in
paraformaldehyde and PBS containing 30% sucrose, and sectioned
into 10 mm sections that were mounted on slides and evaluated for
number of blood vessels.
Supporting Information
Figure S1 miR-101 and EZH2 modulation and function-
ality in HUVECs. (A) qRT-PCR analysis of miR-101 levels in
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HUVECs exposed to U87 secreted factors (n = 3). (B) HUVECs
protein expression analysis of EZH2 following culturing in either
EBM, EGM or EBM derived from U87 glioblastoma cells.
Numbers indicate the relative expression of EZH2 compared to
cells cultured in EBM. (C) HUVECs protein expression analysis of
EZH2 and H3K27me3 following transfection of HUVECs with
pre-miR-101, EZH2 siRNA, non-related control molecules or
treatment with DZNep. Numbers indicate relative EZH2 protein
expression normalized against b-Actin expression. (D) HUVECs
were cultured on Matrigel coated plates in EGM. Inhibition of
EZH2 in HUVECs, either by transfection with pre-miR-101 or
EZH2 siRNA, significantly reduced tubule formation as compared
to control cells. Tubule formation was assessed as tubule length.
(n = 4) Error bars indicate s.d. *p,0.05, ***p,0.001, t test.
(TIF)
Figure S2 HBMVEC proliferation. (A) HBMVEC prolifer-
ation over 24 h as measured by WST assay following transfection
of HBMVEC with pre-miR-101, EZH2 siRNA, non-related
control molecules or treatment with DZNep (n= 5). (B) HBMVEC
proliferation over 72 h as measured by WST assay following
transfection of HBMVEC with pre-miR-101, EZH2 siRNA, non-
related control molecules or treatment with DZNep (n= 5).
(TIF)
Figure S3 In vivo proliferation. (A) Immunohistochemical
staining for Ki67 in glioblastoma sections harvested from U87
tumor bearing mice treated with either PBS or DZNep. Scale bar
= 50 mm.
(TIF)
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